However you look at our strategic global locations: 5 early phase clinical units, 3 continents, 2 hemispheres, 4 unique regulatory environments; PAREXEL Early Phase offers you the unique advantage that we operate as 1 global team. With harmonized processes and global SOPs across our global network you can be sure that you will receive consistent, reliable, high quality data no-matter which location you select for your studies.
We are the only CRO with ownership of early phase units on 3 continents enabling us to ensure your studies can be placed in a location that will provide you with the best advantage - opportunities to accelerate your timelines, reach of diverse patient populations, access to specialized expertise, ability to run studies at multiple sites and utilization of regulatory strategies. All of our units offer studies in healthy volunteers and patient populations.
PAREXEL Early Phase has over 400 beds - among the largest capacities worldwide.
PAREXEL Early Phase has carefully chosen locations across the globe for Phase I/IIa studies that allow us to help you meet your goals and milestones:
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.